NCT00312598View on ClinicalTrials.gov

Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine

CompletedOBSERVATIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

SchizophreniaSchizoaffective DisorderSchizophreniform DisorderMood Disorders

Interventions

DRUG

Aripiprazole

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT00312598 - Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine | Biotech Hunter | Biotech Hunter